Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial Article

Lassman, Andrew B, Pugh, Stephanie L, Wang, Tony JC et al. (2023). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial . NEURO-ONCOLOGY, 25(2), 339-350. 10.1093/neuonc/noac173

Open Access Industry Collaboration International Collaboration

cited authors

  • Lassman, Andrew B; Pugh, Stephanie L; Wang, Tony JC; Aldape, Kenneth; Gan, Hui K; Preusser, Matthias; Vogelbaum, Michael A; Sulman, Erik P; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian S; Gilbert, Mark R; Bain, Earle E; Blot, Vincent; Ansell, Peter J; Samanta, Suvajit; Kundu, Madan G; Armstrong, Terri S; Wefel, Jeffrey S; Seidel, Clemens; de Vos, Filip Y; Hsu, Sigmund; Cardona, Andres F; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard A; Gedye, Craig; Bourg, Veronique; Wick, Antje; Curran, Walter J; Mehta, Minesh P

sustainable development goals

authors

publication date

  • February 14, 2023

published in

keywords

  • ABT-414
  • ADJUVANT TEMOZOLOMIDE
  • AMPLIFICATION
  • ANTIBODY-DRUG CONJUGATE
  • Clinical Neurology
  • EFFICACY
  • EGFR
  • GROWTH-FACTOR RECEPTOR
  • Life Sciences & Biomedicine
  • MONOCLONAL-ANTIBODY
  • MUTATIONS
  • NEUROCOGNITIVE FUNCTION
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology
  • TUMORS
  • antibody drug conjugate
  • depatuxizumab mafodotin
  • glioblastoma
  • phase III

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 339

end page

  • 350

volume

  • 25

issue

  • 2